Transcriptomic profiling unveils novel therapeutic options for drug-resistant temporal lobe epilepsy

Area of Science:

• Neuroscience
• Genomics
• Pharmacology

Background:

• Drug-resistant epilepsy affects 25-30% of patients, with temporal lobe epilepsy being the most common subtype.
• Traditional drug discovery is costly and has a high clinical trial failure rate.
• Drug repurposing offers a more efficient alternative for developing new epilepsy treatments.

Purpose of the Study:

• To identify potential drug candidates for drug-resistant temporal lobe epilepsy (DR-TLE) through drug repurposing.
• To utilize transcriptomic profiling to guide the selection of candidate drugs.
• To find novel therapeutic strategies for patients with refractory epilepsy.

Main Methods:

• RNA sequencing (RNA-Seq) was performed on hippocampal tissue from DR-TLE patients and controls.
• Differential gene expression analysis identified key genes associated with DR-TLE.
• Transcriptomic data was used to screen drug databases for repurposing candidates.

Main Results:

• 887 differentially expressed genes were identified between DR-TLE patients and controls.
• 74 potential drug candidates were found across multiple databases.
• 11 drug candidates capable of crossing the blood-brain barrier were selected, with 5 top candidates identified after further analysis.

Conclusions:

• Erlotinib, danazol, rucaparib, ponatinib, and panobinostat are proposed as potential treatments for DR-TLE.
• These candidates were selected based on differential RNA-Seq profiling and their potential to modulate epileptogenesis.
• The study highlights the utility of drug repurposing and transcriptomic analysis in addressing treatment-resistant epilepsy.